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CASE REPORTMorbilliform eruption in a patient receiving
intravesical Bacilli Calmette-Guerin
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papules on the anterior trunk.
Abbreviation used:
BCG: Bacilli Calmette-GuerinINTRODUCTION
Widely known as a vaccine against tuberculosis,
Bacilli Calmette-Guerin (BCG) is also known to have
antimalignant properties. Intravesical BCG immuno-
therapy is used in the treatment of superficial bladder
cancer. It is postulated that the BCG bacilli trigger a
cascade that leads to increased levels of interleukin-
12 and interferon gamma production, which mediate
tumor destruction.1 Major side effects occur in less
than 5% of those treated and are secondary to
dissemination of the bacilli through vesicoureteral
reflux or hematogenous spread.2
CASE REPORT
A 63-year-old white man with urothelial
carcinoma of the bladder undergoing intravesical
Tice BCG treatments had a pruritic cutaneous
eruption on his right arm and a subjective fever 1
day after his third instillation of intravesical BCG.
Two days later, parotid gland enlargement
developed, and the patient was given ampicillin by
his primary care physician for possible parotitis.
After 1 dose of ampicillin, the eruption spread to
his trunk and face. The physician administered a
steroid injection and switched the medication to
ciprofloxacin, which resulted in temporary improve-
ment of symptoms.
Four days later, when the patient presented to the
urology clinic for his fourth instillation of intravesical
BCG, he was febrile, so the treatment was withheld.
Several hours later he had chills, myalgias, and
recurrence of his skin eruption.
On physical examination, he was noted to
have multiple pink macules coalescing into patchescal Student at The University of Texas Medical School at
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030. E-mail: susanchon@mdanderson.org.involving approximately 30% of the back and 20% of
the anterior trunk and multiple 2- to 6-cm macules
and papules on the bilateral upper and lower
extremities (Fig 1). A punch biopsy found sparse
superficial perivascular dermatitis with focal minimal
spongiosis, consistent with a dermal hypersensitivity
reaction.
Increasing clinical suspicion of systemic hyper-
sensitivity reaction to BCG dissemination prompted
the initiation of antituberculous therapy with
isoniazid, rifampin, and levofloxacin. After 1 week
of therapy, the patient experienced symptomatic
improvement, so this regimen was continued for
3 months, and he had complete resolution. FurtherJAAD Case Reports 2015;1:30-1.
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in this patient because of this reaction.
DISCUSSION
Systemic absorption of BCG into the bloodstream
and reactivation of the attenuated bacilli is known as
BCG-osis.3 Early BCG-osis presents with fever and
other nonspecific constitutional symptoms. Systemic
sequela can include abnormal hematologic and
liver function tests, respiratory comprise, and multi-
organ failure. Very few reports specify cutaneous
manifestations; skin findings can take the form of
purpuric patches, pityriasis rosealike eruption, or a
morbilliform eruption, as in our patient.4,5 Clinical
recognition of BCG infection is challenging, but this
entity should be considered in the differential
diagnosis of patients with a recent exposure to
BCG and an unexplained, rapid-onset, widespread
skin eruption. Because BCG reactivation can be fatal,providers must have a low threshold to begin
antituberculous therapy.REFERENCES
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